Serum concentrations of VEGF and TGF-β1 during exclusive enteral nutrition in IBD

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 2, 2011, Pages 150-155

  Wedrychowicz, Andrzej ^a   Kowalska Duplaga, Kinga ^a   Jedynak Wasowicz, Urszula ^a   Pieczarkowski, Stanislaw ^a   Sladek, Malgorzata ^a   Tomasik, Przemyslaw ^a   Fyderek, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

children; exclusive enteral nutrition; inflammatory bowel disease; transforming growth factor beta 1; vascular endothelial growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CALORIC INTAKE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; ENTERIC FEEDING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTAKE; PROTEIN SYNTHESIS; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS; WEIGHT GAIN;

ADOLESCENT; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DIETARY PROTEINS; ENERGY INTAKE; ENTERAL NUTRITION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTORS; WEIGHT GAIN;

EID: 79961184283     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182144c74     Document Type: Article

References (45)

1. Ballinger AB, Camacho-Hubner C, Croft NM. Growth failure and nutritional inflammation. Q J Med 2001;94:121-5.
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(suppl 1):S3- 9. (Pubitemid 43068428)
3. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomised controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53. (Pubitemid 43825808)
4. Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006;38:381-7. (Pubitemid 44356207)
5. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15. (Pubitemid 30456568)
6. Gonzales-Huix F, de Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993;34:778-82. (Pubitemid 23185103)
7. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9. (Pubitemid 30145315)
8. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996;7:363-74. (Pubitemid 26331991)
9. Afuwape AO, Kiriakidis A, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 2002;17:961-72. (Pubitemid 34784680)
10. Schmidt-Weber CB, Blaser K. Regulation and role of transforming growth factor-beta in immune tolerance induction and inflammation. Curr Opin Immunol 2004;16:709-16. (Pubitemid 39423658)
11. Yamamoto T, Nakahigashi M, Umegae S, et al. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005;11:580-8. (Pubitemid 40826346)
12. Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. JPEN J Parenter Enteral Nutr 2005;29:126-33.
13. IBD Working Group of the ESPGHAN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7.
14. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
15. Ryzko J, Socha J, Woynarowski M, et al. Validation of disease activity score indexes for inflammatory bowel disease. Surg Childh Intern 1996;1:17-21.
16. Cole TJ, Donnet ML, Stanfield JP. Weight-for-height indices to assess nutritional status-a new index on a slide rule. Am J Clin Nutr 1981;31: 1935-43. (Pubitemid 12235281)
17. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007;52:2920-5. (Pubitemid 47512546)
18. Prantera S, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when and how. Curr Opin Gastroenterol 2009; 25:329-33.
19. Uehara T, Kato K, Ohkusa T, et al. Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol 2010;(suppl 1): S62-6.
20. Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter study. Am J Gastroenterol 2010;105:1820-9.
21. Akobeng AK. Crohn's disease: current treatment options. Arch Dis Child 2008;93:787-92.
22. Lochs H, Dejong C, Hammarquist F, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr 2006;25:260-74. (Pubitemid 43811680)
23. Day AS, Whitten KE, Sidler M, et al. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008; 27:293-307.
24. Zachos M, Tondeur M, Griffiths A. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;1:CD000542.
25. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008;52:867-74.
26. O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2006;20:561-73.
27. Griga T, Voigt E, Gretzer B, et al. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 1999;46:920-3. (Pubitemid 29224765)
28. Ferrari G, Cook BD, Terushkin V, et al. Transforming growth factor-beta 1 (TGF-beta 1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009;219: 449-58.
29. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
30. Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001;49:190-8. (Pubitemid 32675110)
31. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad 7 restores TGF-beta 1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-9. (Pubitemid 32777740)
32. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-55.
33. Griga T, Gutzeit A, Sommerkamp C, et al. Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:175-9. (Pubitemid 29103579)
34. Griga T, May B, Pfisterer O, et al. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 2002;49:116-23. (Pubitemid 34289498)
35. Griga T, Tromm A, Spranger J, et al. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:504-8. (Pubitemid 28277250)
36. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96. (Pubitemid 32368033)
37. Paleolog E. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4: S81-90.
38. Paleolog E, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNF-alpha and IL-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65. (Pubitemid 28313429)
39. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission of ulcerative colitis. Cochrane Database System Rev 2006;3:CD005112.
40. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2003;1:CD003459.
41. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7. (Pubitemid 44665475)
42. Sturm A, Schulte C, Schatton R, et al. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:445-50. (Pubitemid 30218951)
43. Sambuelli A, Diez RA, Sugai E, et al. Serum transforming growth factor-beta 1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment Pharmacol Ther 2000;14:1443-9.
44. Bannerjee K, Camacho-Huebner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004;38:270-5.
45. Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Isr Med Assoc J 2008;10:503-7.